**
In a striking revelation, internal records indicate that senior officials from the Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, to discuss critical litigation matters surrounding the controversial herbicide glyphosate. This meeting, held on June 17, 2025, comes in the wake of numerous lawsuits alleging that the chemical, found in products like Roundup, is linked to cancer. The implications of this encounter bring to light the potential sway of corporate interests over regulatory actions during the Trump administration.
Meeting in the Spotlight
The meeting involved key figures from the EPA, including Lee Zeldin, the agency’s administrator, and Nancy Beck, who previously held a senior role at the American Chemistry Council. This gathering was ostensibly a routine part of the regulatory process, yet the timing is particularly significant. Just weeks later, the Supreme Court requested input from the Trump administration regarding Bayer’s case, which aims to limit the company’s liability in light of claims that it failed to adequately warn users about cancer risks associated with glyphosate.
Bayer has been embroiled in litigation with thousands of plaintiffs claiming that their use of glyphosate-based products resulted in cancer diagnoses. The company’s strategy hinges on persuading the Supreme Court to rule that if the EPA does not mandate a cancer warning, Bayer cannot be held accountable for not providing one. This argument has met with mixed reactions from various courts, and while some have sided with Bayer, others have rejected this line of defence.
The Trump Administration’s Support
Following the June meeting, the Trump administration’s backing of Bayer has intensified. In a filing submitted to the Supreme Court on December 1, 2025, solicitor general D. John Sauer advocated for the court to hear Bayer’s appeal. The subsequent decision by the Supreme Court to consider the case, with a hearing date set for April 27, 2026, marks a pivotal moment in the ongoing saga surrounding glyphosate.
Moreover, the administration took further measures to protect glyphosate production, invoking the Defense Production Act in February 2026. This move granted certain protections to glyphosate manufacturers, including Bayer, and signalled a strong governmental endorsement of the company’s interests.
Growing Concerns Over Corporate Influence
Critics have voiced alarm over the apparent ease with which Bayer’s executives have engaged with high-ranking EPA officials. Nathan Donley, the environmental health science director at the Center for Biological Diversity, expressed his concerns, stating, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.”
This sentiment is echoed by legal experts who highlight the disparity in access to regulatory discussions. Whitney Di Bona, an attorney focused on consumer safety, questioned whether the EPA afforded similar opportunities to the thousands of individuals adversely affected by glyphosate.
Naomi Oreskes, a prominent historian of science, commented on the troubling trend of corporate leaders having direct channels to government officials while ordinary citizens remain unheard. Such dynamics raise pressing questions about the integrity of regulatory processes and the balance of power between corporate interests and public health.
Voices of the Advocacy Community
The meeting has not gone unnoticed by advocacy groups. Zen Honeycutt, founder of Moms Across America, noted that this pattern of corporate coercion is nothing new. While her organisation has sought dialogue with the EPA regarding the regulation of harmful pesticides, tangible changes have yet to materialise.
The juxtaposition of corporate lobbying against the backdrop of public health concerns underscores the urgent need for transparency and accountability in regulatory frameworks. Advocacy groups continue to pressure the EPA to prioritise the voices of those impacted by glyphosate, pushing for meaningful action rather than mere discussions.
Why it Matters
As the debate over glyphosate continues to unfold, the implications of this meeting extend far beyond Bayer’s litigation strategies. It underscores a troubling intersection of corporate influence and public health policy, highlighting the significant power dynamics at play within regulatory agencies. The ongoing scrutiny of these interactions poses essential questions about the integrity of regulatory processes and the extent to which corporate interests may shape policy decisions that profoundly affect the health of millions. The outcome of this case could set a precedent for how similar disputes are managed in the future, making it imperative for the public to remain informed and engaged.
